Sandy Spring Bank lifted its position in GlaxoSmithKline PLC (NYSE:GSK) by 1.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,915 shares of the pharmaceutical company’s stock after purchasing an additional 150 shares during the quarter. Sandy Spring Bank’s holdings in GlaxoSmithKline PLC were worth $557,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in GSK. Bronfman E.L. Rothschild L.P. grew its position in GlaxoSmithKline PLC by 45.4% in the first quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock valued at $102,000 after acquiring an additional 753 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC grew its position in GlaxoSmithKline PLC by 1,747.4% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock valued at $105,000 after acquiring an additional 2,359 shares during the period. Proficio Capital Partners LLC grew its position in GlaxoSmithKline PLC by 233.0% in the first quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock valued at $122,000 after acquiring an additional 1,990 shares during the period. Heritage Trust Co bought a new stake in GlaxoSmithKline PLC in the first quarter valued at $123,000. Finally, Westwood Holdings Group Inc. grew its position in GlaxoSmithKline PLC by 15.7% in the first quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock valued at $124,000 after acquiring an additional 400 shares during the period. Hedge funds and other institutional investors own 9.28% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The original version of this report can be viewed at https://www.chaffeybreeze.com/2017/09/18/sandy-spring-bank-purchases-150-shares-of-glaxosmithkline-plc-gsk.html.
GSK has been the topic of a number of analyst reports. Zacks Investment Research cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, July 21st. J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline PLC in a report on Monday, July 24th. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BidaskClub cut GlaxoSmithKline PLC from a “sell” rating to a “strong sell” rating in a report on Monday, July 24th. Finally, Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a report on Friday, May 26th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have issued a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $46.00.
GlaxoSmithKline PLC (GSK) traded down 0.35% during midday trading on Monday, hitting $40.10. The stock had a trading volume of 642,458 shares. The stock has a market capitalization of $98.00 billion, a price-to-earnings ratio of 39.62 and a beta of 1.03. GlaxoSmithKline PLC has a 52 week low of $37.20 and a 52 week high of $44.53. The company’s 50 day moving average price is $39.80 and its 200-day moving average price is $41.77.
GlaxoSmithKline PLC (NYSE:GSK) last posted its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analysts’ expectations of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. Equities analysts anticipate that GlaxoSmithKline PLC will post $2.87 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Investors of record on Friday, August 11th will be paid a $0.491 dividend. The ex-dividend date of this dividend is Wednesday, August 9th. This is a boost from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a dividend yield of 4.88%. GlaxoSmithKline PLC’s dividend payout ratio (DPR) is presently 197.00%.
About GlaxoSmithKline PLC
GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.
Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.